ArisGlobal’s LifeSphere MultiVigilance Goes Live with Top 5 Pharma, Delivering a Next-Generation Safety System to 2,300+ End Users

Dec 10, 2019

The Implementation, Delivered On-Time via ArisGlobal’s Services Team, Enables the Top 5 Pharma to Process 1 Million Adverse Event Cases Annually

MIAMI, FL DECEMBER 10, 2019 – ArisGlobal, the visionary provider of drug development technology for the life sciences industry, today announced that it has successfully delivered the industry’s largest drug safety system implementation, going live on-time with its next-generation LifeSphere® MultiVigilance offering. The implementation, handled by ArisGlobal’s in-house Services team, required the migration of 6.8 million legacy cases, the training of more than 2,300 end users and tight coordination with the customer, a top 5 global pharma that was experiencing issues with its legacy drug safety technology systems.

To handle such a large-scale implementation, ArisGlobal made use of its Organizational Readiness offering, a solution that provides scalable change management, end user training and managed services, to ensure a smooth transition for the customer. The customer, having vetted other industry offerings during an extensive RFP process, ultimately selected ArisGlobal thanks to its innovative cloud technology, flexible out-of-the-box configuration codeveloped with industry leaders, and proven ability to deliver a large scale implementation that will ultimately process more than 1 million adverse event cases per year. After a successful go-live, the relationship is now growing to include other offerings in ArisGlobal’s LifeSphere solution portfolio.

“To deliver an end-to-end drug safety system to more than 2,300 end users is no easy feat,” said Ashok Katti, ArisGlobal’s COO & President, APAC. “But to go-live on time, having deployed a full-scale training and change management program, with no critical issues, is truly a testament to the strong relationship that we have built with the customer. We’re grateful for their partnership and look forward to a bright future together.

ArisGlobal’s LifeSphere MultiVigilance 10 is the industry’s only end-to-end safety system offering production-ready automation. Built hand in hand with industry leaders like the FDA and featuring brand new architecture and an intuitive design, LifeSphere MultiVigilance 10 represents a new era in drug safety technology.

Learn more: For more on LifeSphere MultiVigilance 10, visit: https://www.arisglobal.com/products/lsmv10/

LATEST NEWS

About ArisGlobal

ArisGlobal is transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary Nava® cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® is a unified platform that boosts efficiency, ensures compliance, delivers actionable insights, and lowers total cost of ownership through multi-tenant SaaS architecture.

Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China. For more updates, follow ArisGlobal on LinkedIn and Twitter.

Additional Information

Connect with ArisGlobal on LinkedIn: linkedin.com/company/aris-global
Follow @Aris_Global on Twitter: twitter.com/aris_global

Contact

Alberto Cantor
ArisGlobal
+1 609-360-4042 | acantor@arisglobal.com